Journal Home
Search for

Volume 90, Issue 1, Pages 60-65 (January 2009)


View previous. 12 of 30 View next.

Significance of breast boost volume changes during radiotherapy in relation to current clinical interobserver variations

Coen HurkmansCorresponding Author Informationemail address, Marjan Admiraal, Maurice van der Sangen, Ingrid Dijkmans

Received 13 July 2007; received in revised form 29 November 2007; accepted 6 December 2007. published online 21 January 2008.

Abstract 

Background and purpose

Nowadays, many departments introduce CT images for breast irradiation techniques, aiming to obtain a better accuracy in the definition of the relevant target volumes. However, the definition of the breast boost volume based on CT images requires further investigation, because it may not only vary between observers, but it may also change during the course of treatment. This study aims to quantify the variability of the CT based visible boost volume (VBV) during the course of treatment in relation to the variability between observers.

Materials and methods

Ten patients with stage T1–2 invasive breast cancer treated with breast conservative surgery and post surgical radiotherapy were included in this study. In addition to the regular planning CT which is obtained several days prior to radiotherapy, three additional CT scans were acquired 3, 5 and 7 weeks after the planning CT scan. Four radiation oncologists delineated the VBV in all scans. Conformity of the delineations was analysed both between observers, and between scans taken at different periods of the radiotherapy treatment.

Results

The VBV averaged over all patients decreased during the course of the treatment from an initial 40cm3 to 28cm3, 27cm3 and 25cm3 after 3, 5 and 7 weeks, respectively. Assuming the VBV to be spherical, this corresponds to a reduction in diameter of 5–6mm. More detailed analysis revealed that this reduction was more pronounced when radiotherapy started within 30 days after surgery. These boost volume changes over time were found to be significant (p=0.02) even in the presence of interobserver variations. Moreover, the conformity index (CI) for the volume changes was of the same magnitude as the conformity index for the interobserver variation (0.25 and 0.31, respectively).

Conclusions

Breast boost volume variations during a course of radiotherapy are significant in relation to current clinical interobserver variations. This is an important finding to take into account when introducing CT based planning, especially when applying an integrated boost technique.

Article Outline

Abstract

Methods and materials

Patient data

Definition of volumes

Volume changes over time

Interobserver variations

Significance of volume changes in the presence of observer variations

Results

Volume changes over time

Interobserver variations

Significance of time trends and observer variations

Discussion

Conclusions

Acknowledgment

References

Copyright

Radiotherapy treatment for breast cancer has changed rapidly with the introduction of CT based planning. Traditionally, conventional simulation and treatment of the whole breast were followed by conventional simulation and treatment of the breast boost volume. Currently, conventional simulation is often replaced by CT based planning. Some centres have now replaced the two conventional simulations of the whole breast and the boost volume separately, by a planning based on one set of CT data acquired prior to the first radiotherapy fraction. The boost volume is then delineated at the start of the total treatment, assuming the boost volume does not change significantly over the course of treatment.

However, little is known about the change of the boost volume over the time of treatment [8], [11] and data about the interobserver variation in delineation of the breast boost volume are limited [1], [13], [14]. If volume changes are of the same magnitude as the interobserver variation, the use of only the initial CT scan for planning might even decrease instead of increasing our treatment accuracy.

Before introducing IMRT or integrated boost techniques it is important to quantify these variations in order to safely and effectively introduce these novel techniques into the clinic [5], [7].

The goal of our study was to quantify volume changes of the visible boost volume (VBV) during the course of treatment and to compare these changes with the interobserver variability.

Methods and materials 

return to Article Outline

Patient data 

Ten randomly selected patients with stage T1–2 invasive breast cancer treated with breast conservative surgery were included in this study. None of these patients received adjuvant chemotherapy. For each patient a standard radiotherapy planning CT scan was acquired several days before radiotherapy. The radiotherapy consisted of 25 fractions of 2Gy/fraction, 5 days per week to the whole breast, followed by a boost of 16Gy in eight fractions to the boost PTV. CT slice thickness was 3-mm with 3-mm separation, and the patient was positioned supine with both arms placed in an armrest above the head. Before scanning, the radiation technologist placed a copper wire around the palpable breast tissue in order to facilitate breast target volume delineation.

In addition to the planning CT, repeat CT scans were acquired 3, 5 and 7 weeks after acquisition of the planning CT. These repeat CT scans were automatically registered to the planning CT scan using the Pinnacle v7.6 image fusion module (Philips Medical Systems). The registration was visually inspected focussing mainly on the ribs on the ipsilateral side, and adapted if necessary. Registering the ribs was considered to correspond best with the widespread method of patient positioning at the treatment unit using (on-line) epid corrections.

Definition of volumes 

Four radiation oncologists delineated the VBV. Because previous studies have shown that providing guidelines can improve consistency among observers, a set of guidelines for contouring was developed [13]. These guidelines were first applied by all four radiation oncologists on one test patient case, after which the results were discussed with the observers. This was done to detect and correct ambiguities in the guidelines.

To avoid ambiguity, we will use the term visible boost volume (VBV) to describe the volume that was delineated. From this volume, a CTV and PTV can be derived using appropriate VBV to CTV and CTV to PTV margins, which may differ between institutes. By presenting our results in this way, we avoid them to be influenced by our a-priori choice of margins, but rather show results based on the observable features in the CT scans.

In the guidelines, we defined the VBV as the visible lumpectomy cavity including possible seroma, haematoma and all surgical clips. Furthermore, the VBV should be delineated in all CT slices extending over the VBV. Standardized window and level settings were used by all observers and each observer kept at least 1 week between subsequent delineations of CT scans of the same patient. In our institute, the boost CTV is defined as the expansion of the VBV by 1cm minus the tumour free resection margin and excluding the skin (with a margin of 0.5cm), the ribs and the pectoralis muscle. An additional margin of 1cm is taken into account in the expansion from boost CTV to boost PTV, again excluding the skin with a margin of 0.5cm.

Volume changes over time 

The boost volume was calculated for all delineations and absolute and relative volume differences between CT sessions were analysed for each patient separately. Using the Pinnacle software, the common and encompassing VBVs of the four CT datasets per patient were generated. The ratio of the common and encompassing VBV of a patient, referred to as the conformity index (CIovertime), was calculated to analyse the variation of the VBV over time. If no variation is noted this ratio is equal to one. On the other hand, if no volume is common to all four delineated volumes, the ratio equals 0. For each patient, the CIovertime is calculated for each observer separately, and then averaged over the observers.

In order to quantify the relevance of replanning, we represent the VBVs by spheres of the same volume and analyse the difference in diameter of the spheres for the first and second CT scan. This gives a quantitative indication of the change in the conformal field sizes that would be found when replanning the treatment based on a CT taken 3 weeks after the first CT.

Interobserver variations 

To detect possible systematic observer differences independent from the absolute delineated volumes, the volumes delineated by the four observers were ranked 1 (smallest delineation) to 4 (largest delineation) per CT dataset. Thus, 40 values per observer were generated (4 datasets per patient times 10 patients). To detect if observer differences are consistent between scans, these rankings were averaged per observer, for the planning CTs and the three consecutive CT datasets separately. If an observer would always delineate the smallest VBV, this will result in averaged rankings of 1. An observer who always delineates the largest VBV would score averaged rankings of 4.

Significance of volume changes in the presence of observer variations 

To determine whether boost volume changes over time and interobserver variations are independent factors, a repeated measures analysis of variance was performed.

Because of the restricted number of measurements, sphericity of the data could not be guaranteed. Therefore the number of degrees of freedom in F was corrected for violation of sphericity (Greenhouse–Geisser correction), which led to slightly higher p values. Statistical calculations were performed using SPSS v12.0 (SPSS Inc.).

Results 

return to Article Outline

Volume changes over time 

In Fig. 1 the visible boost volume per patient is given as a function of the time from lumpectomy (or re-excision if applicable), averaged over the four observers. One can see that there is, for most patients, a decrease of the volume over time. This decrease is most pronounced between CT1 and CT2, for example for patients 1, 2 and 10, for whom the time between surgery and the first CT scan is shortest.


View full-size image.

Fig. 1. Change of VBV as a function of time after surgery. The average volumes drawn by the four observers are shown. The figure is split into two for ease of visualisation (note the different y-axis scaling). The legends refer to the patient numbers.


Patients 1, 4, 5 and 10 had a visible seroma, and it seems that for these patients the volume decrease is in general larger than for patients who did not have a visible seroma. However, the number of patients in this study is too small to perform a valid subgroup analysis on this parameter.

In the approach where the VBVs are assumed to be spherical, the VBV diameter averaged over all patients reduces from scan 1 to scans 2, 3 and 4 (from 43 to 38mm, 37 and 37mm, respectively). This means that replanning at 3, 5 or 7 weeks after the first planning CT will on average result in an estimated field size reduction of 5, 6 or 6mm, respectively.

The variation of the boost volume and boost position over time is illustrated in Fig. 2 for a patient who showed a relatively low CIovertime of 0.1 (patient 5). The low CIovertime indicates a large change in time of either the boost volume, the boost position or both. For this patient the ribs of the four consecutive scans could be matched accurately, with residual differences of the order of a few mm. The larger differences in the contours of the breast over time – as seen in Fig. 2, Fig. 3 – reveal the flexibility of the breast. Large breasts in general show larger contour variations. The breast volume for patient 5 was 2736cm3, while the volume of the other patients ranged between 487 and 1734cm3. The CIovertime was on average 0.25 (range: 0.08–0.36), which can be seen in Fig. 5.


View full-size image.

Example of variation of VBV over time in both volume and place (Patient 5). The delineation of one observer (number 3) is shown. The yellow contour is drawn on the underlying CT dataset. The blue contours are overlays from the other CT datasets.



View full-size image.

Example of a relatively small interobserver variation (Patient 5). The green contour depicts the common volume (Comoverobservers) while the red volume depicts the encompassing volume (Sumoverobservers). Datasets CT1 to CT4 are shown from left to right.


Interobserver variations 

Apart from the large variation in VBV over time, we also found large interobserver variations. The relative volume difference between observers varied widely between CT scans, from 10% for scan 4 for patient 5 (average volume of 43cm3) to 149% for scan 4 for patient 6 (average volume of 37cm3). Absolute volume differences between observers in a single CT scan ranged from 5 to 74cm3 (scan 2 for patient 4, average volume: 14cm3 and scan 2 for patient 1, average volume 77cm3, respectively).

The above examples clearly show that the interobserver variation depends highly on the CT scan. The disagreement between observers is large for e.g. patient 6, in which a diffuse area of denser tissue was visible extending from the skin to the ribs. For e.g. patient 4, whose CT scan was considered easy to delineate because of the presence of a clearly visible seroma in a region of less dense breast tissue, the disagreement between observers is relatively small. For all patients, the observers agree that the decrease in volume is largest from scans 1 to 2 and smaller for the other pairs of consecutive scans.

Compared to the average size of 40cm3 of the volume delineated in the first CT, the consecutive scans 2, 3 and 4 showed an average decrease of 29% (12cm3), 34% (13cm3) and 37% (15cm3), respectively.

In Fig. 3 the axial contours of the common (Comoverobservers) and encompassing (Sumoverobservers) volumes over all observers are shown for patient 5 and one can see that for this patient, the delineations of the four observers correspond relatively well. This can also be concluded from the relatively high conformity index over all observers (CIoverobservers=0.52). Fig. 4 shows that the differences between observers do not change considerably over time. Observer 2 often delineated the largest volume (26/40 delineations), while observer 4 often delineated the smallest volume (20/40 delineations). Delineations by observers 1 and 3 were most often close to the average over all observers. This can also be seen when ranking the size of the delineations: observer 2 scores an average ranking of 3.6 whereas observer 4 scores an average ranking of 1.7.


View full-size image.

Fig. 4. Ranking of delineated volume size per observer for the four CT datasets. The average rank, with ranking from 1 (smallest delineated volume) to 4 (largest delineated volume) per observer over all 10 patients, is shown.


For all scans, the CIoverobservers ranged from 0.11 to 0.52, with an average of 0.31. This is in the same order of the conformity of the variations over time as shown in Fig. 5 (average CIovertime=0.25, range: 0.08–0.36).


View full-size image.

Fig. 5. Conformity indices CIoverobservers (black) and CIovertime (white). When CIoverobservers is larger than CIovertime, this means that the variation over time is larger than the variation between observers.


Significance of time trends and observer variations 

Despite the relatively large interobserver variation, there is a significant decrease in volume between consecutive scans (p=0.02). The decrease in volume between consecutive scans was most prominent between the first and the second CT scan. When the first CT dataset was excluded, the volume decrease was no longer significant (p=0.21). On the other hand, when taking this volume decrease over time into account, the interobserver variation remains significant (p=0.003). This also remained significant when the first CT dataset was left out of the analysis (p=0.002).

Discussion 

return to Article Outline

We analysed the data from 10 patients, for which four consecutive CT scans were available: one planning CT and CT scans obtained 3, 5 and 7 weeks after this first CT scan. Jacobson et al. used the data of 20 patients for which one planning CT and one CT during the 4th or 5th week of treatment were available to determine changes in the lumpectomy cavity [8]. None of these patients received chemotherapy before radiotherapy. Based on the delineations of one observer, they saw that 16 out of 20 patients had more than a 20% decrease from the first to the second volume. In our study, we found an even larger volume decrease with an average of approximately 30%.

In an article concerning the clinical experience of partial breast irradiation, Vicini et al. concisely described a lumpectomy cavity volume decrease of on average 49% in 13/18 patients and an increase of on average 61% in 4/18 patients [15]. The mean and median times between CT scans in these patients were 22 and 17 days, respectively. These findings seem to deviate from the results of Jacobson and our group. However, they a-priory selected these patients on the basis of their large clinical target volume, which might bias their results.

A completely opposite result was found by Kubicek and co-workers who observed a median increase of the lumpectomy cavity of 33% in 31/39 patients in median 40 days [9]. However, in their study a HDR boost was given directly after the first CT scan. This might be the cause of the volume increase.

The presence or absence of seroma or haematoma after surgery or brachytherapy might also influence the results found in our study and the studies mentioned above. Furthermore, whether or not chemotherapy is given before radiotherapy might also play a role. More data about boost volume changes are needed to explain these varying results.

With current IMRT irradiation techniques we are able to plan a highly conformal treatment of the boost volume, using proper margins to account for set-up errors. However, volume changes combined with positional changes of the boost volume during the course of treatment increase the risk of a geographical miss, specifically with highly conformal techniques. This might in turn lead to sub-optimal local control. The influence of these changes on the dose distribution in the boost volume is subject of ongoing research at our department.

In the current literature, much data are available on target volume definition. Numerous articles have been published about CT based whole breast and boost target volume definition. In general, large interobserver variations are found as the glandular breast tissue and boost target volume are not clearly visible on CT [2], [6], [10], [12], [14]. A further reduction of these variations might be accomplished by repeated training of the radiation oncologists, refinement of the definitions of the target volumes and contouring guidelines. Limited data are now becoming available using either MR imaging, ultrasound or PET/CT imaging [3], [4]. Further study is required to estimate the possible advantage of these imaging modalities in this context.

Besides the possible improvements in treatment planning by including more or other imaging data during plan preparation, improvements in plan execution also have to be considered. With the introduction of CT and more conformal boost irradiation techniques, patient set-up verification and correction have become more important. The correction is often calculated using bony anatomy matching of portal images. However, this and other 2D techniques are inadequate to detect the actual boost size and position changes, because this requires full 3D anatomical information. Although it seems obvious to use cone-beam CT for this purpose, its current soft tissue image quality is still poor compared to a normal diagnostic CT-scan.

In our hospital, from May 2007 onwards, all patients who receive radiotherapy of the breast including a boost dose are receiving an integrated boost. Twenty-eight fractions of 1.81Gy to the breast and an additional 0.49Gy to the boost volume are given. This corresponds to a biological equivalent dose in 2Gy fractions of 50 and 66Gy to the breast and boost volume, respectively. Based on our results, we have concomitantly introduced an adaptive radiotherapy procedure, for patients with an initial VBV of 30cm3 or more and for whom the time between the last breast surgery and planning CT is less than 30 days. These patients are treated with an integrated boost plan based on the planning CT for the first 2 weeks of treatment. After 2 weeks a second CT scan is made, and the remainder of the treatment is performed according to a new integrated boost plan based on this new CT scan.

Conclusions 

return to Article Outline

In an a-select population of 10 patients, we observed a significant average visible boost volume decrease of 29% in the first 3 weeks, with a further decrease to 37% after 7 weeks. This volume change is independent of the, also significant, interobserver variation. Thus, both interobserver and volume changes over time should be taken into account for breast boost treatment. This means that with the implementation of an integrated boost technique, one should consider the simultaneous introduction of an adaptive planning strategy. With such an adaptive strategy, boost field size reductions of approximately 5mm can be achieved.

Acknowledgements 

return to Article Outline

We acknowledge Tim Brouwer for his help with the statistical analysis performed in this study. The comments and suggestions of Jorien Cassee, Gert Meijer, Jacco Steenhuijsen, Wim Dries, Danny Schuring and Rogier Janssen are also greatly appreciated.

References 

return to Article Outline

[1]. [1]Benda RK, Yasuda G, Sethi A, et al. Breast boost: are we missing the target?. Cancer. 2003;97:905–909.

[2]. [2]Bentel G, Marks LB, Hardenbergh P, Prosnitz L. Variability of the location of internal mammary vessels and glandular breast tissue in breast cancer patients undergoing routine CT-based treatment planning. Int J Radiat Oncol Biol Phys. 1999;44:1017–1025. Abstract | Full Text | Full-Text PDF (704 KB) | CrossRef

[3]. [3]Coles CE, Cash CJ, Treece GM, et al. High definition three-dimensional ultrasound to localise the tumour bed: a breast radiotherapy planning study. Radiother Oncol. 2007;84:233–241. Abstract | Full Text | Full-Text PDF (694 KB) | CrossRef

[4]. [4]Ford EC, Lavely W, Frassica D, et al. Comparison of PET/CT and CT for delineation of lumpectomy cavity for partial breast irradiation. Int J Radiat Oncol Biol Phys. 2007;66:s225–s226. Full Text | Full-Text PDF (50 KB) | CrossRef

[5]. [5]Guerrero M, Li XA, Earl MA, Sarfaraz M, Kiggundu E. Simultaneous integrated boost for breast cancer using IMRT: a radiobiological and treatment planning study. Int J Radiat Oncol Biol Phys. 2004;59:1513–1522. Abstract | Full Text | Full-Text PDF (330 KB) | CrossRef

[6]. [6]Hurkmans CW, Borger JH, Pieters BR, et al. Variability in target volume delineation on CT scans of the breast. Int J Radiat Oncol Biol Phys. 2001;50:1366–1372. Abstract | Full Text | Full-Text PDF (913 KB) | CrossRef

[7]. [7]Hurkmans CW, Meijer GJ, van Vliet-Vroegindeweij C, van der Sangen MJ, Cassee J. High-dose simultaneously integrated breast boost using intensity-modulated radiotherapy and inverse optimization. Int J Radiat Oncol Biol Phys. 2006;66:923–930. Abstract | Full Text | Full-Text PDF (1290 KB) | CrossRef

[8]. [8]Jacobson G, Betts V, Smith B. Change in volume of lumpectomy cavity during external-beam irradiation of the intact breast. Int J Radiat Oncol Biol Phys. 2006;65:1161–1164. Abstract | Full Text | Full-Text PDF (182 KB) | CrossRef

[9]. [9]Kubicek GJ, Kimler B, Bell M, Wang F. Changes in breast cavity contours after lumpectomy. Int J Radiat Oncol Biol Phys. 2006;66:s222. Full Text | Full-Text PDF (51 KB) | CrossRef

[10]. [10]Landis DM, Luo W, Song J, et al. Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity. Int J Radiat Oncol Biol Phys. 2007;67:1299–1308. Abstract | Full Text | Full-Text PDF (1476 KB) | CrossRef

[11]. [11]Oh KS, Kong FM, Griffith KA, Yanke B, Pierce LJ. Planning the breast tumor bed boost: changes in the excision cavity volume and surgical scar location after breast-conserving surgery and whole-breast irradiation. Int J Radiat Oncol Biol Phys. 2006;66:680–686. Abstract | Full Text | Full-Text PDF (595 KB) | CrossRef

[12]. [12]Petersen RP, Truong PT, Kader HA, et al. Target volume delineation for partial breast radiotherapy planning: clinical characteristics associated with low interobserver concordance. Int J Radiat Oncol Biol Phys. 2007;69:41–48. Abstract | Full Text | Full-Text PDF (1231 KB) | CrossRef

[13]. [13]Pitkanen MA, Holli KA, Ojala AT, Laippala P. Quality assurance in radiotherapy of breast cancer – variability in planning target volume delineation. Acta Oncol. 2001;40:50–55. CrossRef

[14]. [14]Struikmans H, Warlam-Rodenhuis C, Stam T, et al. Interobserver variability of clinical target volume delineation of glandular breast tissue and of boost volume in tangential breast irradiation. Radiother Oncol. 2005;76:293–299. Abstract | Full Text | Full-Text PDF (202 KB) | CrossRef

[15]. [15]Vicini FA, Remouchamps V, Wallace M, et al. Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003;57:1247–1253. Abstract | Full Text | Full-Text PDF (406 KB) | CrossRef

Catharina Hospital, Department of Radiation Therapy, Eindhoven, The Netherlands

Corresponding Author InformationCorresponding author. Catharina Hospital, Department of Radiation Therapy, Michelangelolaan 2, P.O. Box 1350, 5602 ZA Eindhoven, The Netherlands.

PII: S0167-8140(07)00653-6

doi:10.1016/j.radonc.2007.12.001


View previous. 12 of 30 View next.